10-Q: Regeneron Q3 Net Income Rises Amid EYLEA Decline

Regeneron Pharmaceuticals reported increased net income and diluted EPS for Q3 2025, driven by strong Dupixent and Libtayo sales, despite a significant decline in EYLEA revenue and regulatory delays for EYLEA HD and Ordspono.

Summary

• Net income for Q3 2025 increased to $1,460.0 million, up 8.9% from $1,340.6 million in Q3 2024.
• Diluted earnings per share (EPS) rose to $13.62 in Q3 2025, an 18.0% increase from $11.54 in Q3 2024.
• Total revenues for Q3 2025 were $3,754.3 million, a modest 0.9% increase from $3,720.7 million in Q3 2024.
• U.S. EYLEA net product sales declined significantly by 40.5% to $680.6 million in Q3 2025, primarily due to competitive pressures from biosimilars and compounded bevacizumab, and patient transition to EYLEA HD.
• U.S. EYLEA HD net product sales grew by 9.8% to $430.6 million in Q3 2025.
• Collaboration revenue, largely from Dupixent and Kevzara, increased by 18.6% to $1,968.4 million in Q3 2025, with Dupixent and Kevzara global net product sales (recorded by Sanofi) up 27.3% to $5,011.0 million.
• Libtayo global net product sales increased by 26.5% to $365.2 million in Q3 2025.
• Research and development expenses increased by 16.0% to $1,475.0 million in Q3 2025, reflecting ongoing pipeline investments.
• The company repurchased $2,766.9 million of Common Stock during the nine months ended September 30, 2025, with $2.156 billion remaining under current programs.
• A quarterly cash dividend of $0.88 per share was declared, payable in December 2025.

Sentiment

Score: 6

Explanation: While net income and EPS growth are strong, driven by Dupixent and Libtayo, the significant decline in EYLEA sales and the regulatory delays for EYLEA HD and Ordspono due to manufacturing issues introduce considerable uncertainty. The ongoing legal battles, though some with favorable outcomes, also represent persistent headwinds. The company's pipeline progress is mixed, with some successes and some setbacks.

Positives

• Net income increased by 8.9% to $1,460.0 million in Q3 2025, and diluted EPS grew by 18.0% to $13.62.
• Collaboration revenue, primarily from Dupixent, showed strong growth of 18.6% to $1,968.4 million in Q3 2025, driven by a 27.3% increase in global Dupixent and Kevzara sales.
• Libtayo global net product sales increased by 26.5% to $365.2 million in Q3 2025.
• EYLEA HD U.S. net product sales grew by 9.8% to $430.6 million in Q3 2025, indicating successful patient transition and uptake.
• Lynozyfic (linvoseltamab) received approval from both the FDA and EC for relapsed/refractory multiple myeloma.
• Positive Phase 3 trial results were reported for REGN5713-5715 (birch allergy) and REGN1908-1909 (cat allergy), meeting primary and key secondary endpoints.
• The cemdisiran combination trial in myasthenia gravis met its primary and key secondary endpoints, with an NDA submission planned for Q1 2026.
• Garetosmab's Phase 3 trial in FOP met its primary endpoint, with a BLA submission expected in Q4 2025.
• DB-OTO received an FDA Commissioner's National Priority Voucher, and a BLA submission for hearing deficit is expected in Q4 2025.
• The company initiated a quarterly cash dividend program in February 2025 and continued significant share repurchases, with $2.156 billion remaining under authorization.
• A jury awarded Regeneron $135.6 million in compensatory damages and $271.2 million in punitive damages in the Praluent antitrust lawsuit against Amgen.

Negatives

• U.S. EYLEA net product sales declined significantly by 40.5% to $680.6 million in Q3 2025, primarily due to increased competition from biosimilars and compounded bevacizumab, and patient transition to EYLEA HD.
• Total U.S. EYLEA HD and EYLEA net product sales decreased by 27.7% to $1,111.2 million in Q3 2025.
• Inmazeb U.S. net product sales dropped to $0 million in Q3 2025 from $35.6 million in Q3 2024.
• Regulatory delays occurred for EYLEA HD's pre-filled syringe sBLA and Ordspono's BLA due to unresolved inspection findings at the Catalent manufacturing site, leading to a Complete Response Letter (CRL) for both.
• One of two Phase 3 trials for itepekimab in COPD (AERIFY-2) did not meet its primary endpoint, leading to an evaluation of next steps.
• Nexiguran ziclumeran (NTLA-2001) Phase 3 trials were temporarily paused due to a Grade 4 adverse event involving the liver.
• REGN5381 Phase 2 studies in heart failure and uncontrolled hypertension were discontinued.
• The effective tax rate increased to 17.2% in Q3 2025 from 10.2% in Q3 2024, partly due to a $44.5 million charge related to the re-measurement of U.S. net deferred tax assets following the 'One Big Beautiful Bill Act' (OBBBA).
• Bayer collaboration revenue decreased by 11.8% to $344.8 million in Q3 2025, driven by lower EYLEA sales outside the United States.

Risks

• Substantial dependence on the commercial success of EYLEA, EYLEA HD, and Dupixent, with EYLEA facing significant decline due to biosimilar competition.
• Uncertainty regarding the utilization, market acceptance, and commercial success of EYLEA HD, especially with regulatory delays and competition.
• Reliance on third-party payors for coverage and reimbursement, with potential negative impacts from drug pricing regulations (e.g., Inflation Reduction Act, 'most-favored-nation' pricing proposals) and patient affordability constraints (e.g., compounded bevacizumab).
• Significant competition from superior, more established, or cost-effective products, including biosimilars for EYLEA and other anti-VEGF treatments.
• Risks associated with ongoing patent litigation and post-grant proceedings for EYLEA, which could impact market exclusivity and sales.
• Regulatory and development risks, including costly, time-consuming, and uncertain approval processes, potential for serious complications or side effects in clinical trials, and manufacturing suitability challenges.
• Manufacturing and supply chain capacity limitations, reliance on contract manufacturers, and risks of non-compliance with cGMP requirements (e.g., Catalent inspection issues causing regulatory delays).
• Risks from government investigations and legal proceedings (e.g., federal False Claims Act, Anti-Kickback Statute allegations) that could result in civil or criminal penalties, fines, and reputational damage.
• Potential for termination or material breach of collaboration agreements with Sanofi and Bayer, which would significantly harm development, manufacturing, and commercialization efforts.
• Risks related to the increasing use of artificial intelligence-based solutions, including impermissible use or public disclosure of sensitive data, unintended biases, and compliance with evolving regulations.
• Exposure to product liability claims from the testing, manufacturing, marketing, and sale of drugs.
• Risks associated with tariffs and other trade restrictions, particularly concerning China-based suppliers and geopolitical developments.
• Volatility in stock price due to various factors, including clinical trial results, regulatory decisions, competition, and large sales by significant shareholders.
• Potential for future capital raises to result in shareholder dilution or increased indebtedness.

Future Outlook

The company expects to continue incurring substantial expenses for research and development, which are anticipated to expand and require additional resources. Substantial costs related to the commercialization of marketed products are also expected. Financial results are projected to fluctuate based on product sales, R&D efforts, collaboration profits, and income tax expense, with uncertainty surrounding regulatory approval and commercial success of new products or indications. Capital expenditures for the full year 2025 are estimated to be between $850 million and $890 million. Key upcoming regulatory decisions include FDA decisions on EYLEA HD sBLAs for RVO and every 4-week dosing regimen (November 2025), and an EC decision on Dupixent in CSU (Q4 2025). The company plans to submit an application for a new EYLEA HD pre-filled syringe manufacturing filler by January 2026 and expects an FDA decision on an additional vial filler by late December 2025. BLA submissions for garetosmab in FOP and DB-OTO for hearing deficit are expected in Q4 2025, and an NDA for cemdisiran in myasthenia gravis is planned for Q1 2026. Several new Phase 3 studies for allergy treatments and thrombosis are slated for Q4 2025 and H1 2026, with data readouts for Fianlimab in NSCLC and metastatic melanoma also expected in H1 2026.

Management Comments

• We expect to continue to incur substantial expenses related to our research and development activities, and our research and development activities and related costs which are not reimbursed by collaborators are expected to expand and require additional resources.
• We also expect to incur substantial costs related to the commercialization of our marketed products.
• Our financial results may fluctuate from quarter to quarter and will depend on, among other factors, the net sales of our products; the scope and progress of our research and development efforts; the timing of certain expenses; the continuation of our collaborations, in particular with Sanofi and Bayer, including our share of collaboration profits from sales of commercialized products and the amount of reimbursement of our research and development expenses that we receive from collaborators; and the amount of income tax expense we incur, which is partly dependent on the profits or losses we earn in each of the countries in which we operate.
• There is uncertainty surrounding whether or when new products or new indications for marketed products will receive regulatory approval or, if any such approval is received, whether we will be able to successfully commercialize such products and whether or when they may become profitable.

Industry Context

The pharmaceutical industry continues to navigate significant competitive pressures, particularly from biosimilars impacting established blockbuster drugs like EYLEA. The strategic shift towards next-generation formulations and extended-dosing regimens, exemplified by EYLEA HD, is a critical competitive response in the ophthalmology market. Regulatory scrutiny on manufacturing quality and supply chain reliability, as highlighted by the Catalent inspection issues, remains a pervasive industry challenge affecting approval timelines. Furthermore, evolving drug pricing regulations, such as the Inflation Reduction Act and proposals for 'most-favored-nation' pricing, along with patient affordability concerns, continue to shape market access and revenue potential across the sector. The increasing integration of artificial intelligence in drug discovery and development presents both opportunities for innovation and new regulatory and ethical considerations for the industry.

Comparison to Industry Standards

• EYLEA's significant sales decline (-40.5% in Q3 2025) due to biosimilar competition and patient affordability issues (compounded bevacizumab) is consistent with the typical impact seen on originator biologics after patent expiry and biosimilar launch, comparable to the market dynamics experienced by Amgen's Neulasta or AbbVie's Humira in certain markets.
• The strong growth of Dupixent (global sales up 27.3%) and Libtayo (global sales up 26.5%) demonstrates successful commercialization of newer assets, outperforming many industry peers in their respective therapeutic areas. Dupixent's performance in atopic dermatitis, asthma, and CRSwNP continues to set a high bar for immunology franchises.
• Regulatory delays for EYLEA HD and Ordspono due to manufacturing site issues (Catalent) highlight a common industry challenge where reliance on third-party contract manufacturing organizations (CMOs) can introduce external risks to approval timelines, as seen with other companies facing similar supply chain or quality control issues.
• The jury verdict awarding Regeneron $406.8 million in damages against Amgen in the Praluent antitrust case is a significant win, potentially setting a precedent for anti-competitive bundling practices in the pharmaceutical industry.

Corporate Governance

Legal Proceedings

• **EYLEA Patent Litigation**: Settlements with Mylan/Biocon, Formycon, Celltrion, and Sandoz precluding biosimilar launches until H2 2026 or December 31, 2026. Ongoing litigation against Amgen, with a preliminary injunction denied and appeal affirmed. EPO opposition proceedings for '306, '992, and '049 Patents are ongoing. Favorable rulings in Germany (injunction against Formycon for '691 Patent infringement) and Netherlands (injunction against Samsung Bioepis for '691 and '306 Patent infringement). Unfavorable ruling in UK (Formycon and Samsung Bioepis biosimilars do not infringe '691 and '306 Patents, '306 Patent invalidated). Canadian lawsuits against Amgen Canada and Sandoz Canada settled and dismissed. South Korean court granted a preliminary injunction against Samsung on the '811 Patent, but denied it against Celltrion.
• **EYLEA Pre-filled Syringe Antitrust Lawsuit**: An antitrust lawsuit against Novartis Pharma AG, Novartis Pharmaceuticals Corporation, and Novartis Technology LLC, alleging Sherman Antitrust Act violations and tortious interference, was transferred back to the Southern District of New York.
• **Praluent Antitrust Lawsuit**: A jury awarded Regeneron $135.6 million in compensatory damages and $271.2 million in punitive damages in the antitrust lawsuit against Amgen Inc., alleging an anticompetitive bundling scheme. Post-trial motions have been filed by both parties.
• **Praluent Patent Litigation (Europe)**: Sanofi filed an action in the Munich UPC seeking revocation of Amgen's European Patent No. 3,666,797, which was revoked by the UPC (Amgen appealed). Amgen's infringement lawsuit against Regeneron/Sanofi was stayed. The EPO Opposition Division upheld the '797 Patent (Regeneron/Sanofi appealed).
• **Department of Justice Matters**: The U.S. Attorney's Office for the District of Massachusetts filed a civil complaint alleging Anti-Kickback Statute violations related to patient assistance funds, with ongoing summary judgment motions and appeals. A U.S. Department of Justice investigation into remuneration paid to physicians led to a qui tam complaint, with federal claims dismissed and state claims declined, now under appeal. A U.S. Department of Justice investigation into alleged kickbacks to distributors/ophthalmology practices and inflated reimbursement rates for EYLEA resulted in a partial intervention by the DOJ and several states, with the company's motion to dismiss denied and answers/counterclaims filed.
• **Other Payors Lawsuits**: Multiple lawsuits by UHC, Humana, BCBS, MMO, Horizon, Local 464A, and Medicare Advantage plans, alleging state law and RICO violations related to conduct in DOJ civil complaints. Most are stayed pending resolution of DOJ proceedings.
• **Shareholder Derivative Complaints**: Multiple complaints filed against board members and executive officers alleging breach of fiduciary duties, federal securities law violations, waste of corporate assets, and unjust enrichment related to DOJ matters and director compensation. Most are stayed or motions to dismiss/remand are pending.
• **Sanofi Litigation**: Regeneron filed a lawsuit against Sanofi alleging breach of the Collaboration Agreement regarding access to material information and audit rights. Sanofi filed a motion to dismiss.

Related Party Transactions

• Collaboration agreements with Sanofi for Dupixent, Kevzara, and itepekimab, involving shared profits, manufacturing reimbursement, and R&D expense obligations.
• Collaboration agreement with Bayer for EYLEA HD and EYLEA outside the United States, involving shared profits, manufacturing reimbursement, and R&D expense obligations.
• Royalty payments to Sanofi on global Libtayo sales.
• Royalty payments received from Sanofi on Praluent sales outside the United States.
• Royalty and milestone payments to Alnylam for cemdisiran and other product candidates from the collaboration.
• Collaboration with Intellia for Nex-z, where development expenses are shared (75% Intellia / 25% Regeneron) and Regeneron is entitled to 25% of any commercialization profits.

Stakeholder Impact

• **Shareholders**: Positive impact from increased net income, EPS, and ongoing share repurchase program and quarterly dividends. Potential negative impact from EYLEA sales decline, regulatory delays, and significant legal proceedings could affect stock price volatility.
• **Patients**: Potential benefits from new approvals (Lynozyfic, Dupixent in CSU/bullous pemphigoid) and pipeline progress (cemdisiran, garetosmab, DB-OTO). Delays for EYLEA HD pre-filled syringe and Ordspono could delay access to improved treatments. Concerns about patient affordability for EYLEA.
• **Employees**: Continued investment in R&D and manufacturing facilities suggests stable to growing employment opportunities. Risks from legal proceedings and business disruptions could impact morale or job security.
• **Collaborators (Sanofi, Bayer, Intellia, Hansoh)**: Continued collaboration revenue and R&D cost sharing. The Sanofi litigation introduces uncertainty into that key partnership. Bayer collaboration revenue decreased due to EYLEA sales decline.
• **Customers (Distributors, Healthcare Providers)**: Impacted by product availability (EYLEA HD delays), pricing, and reimbursement policies. High customer concentration (Customer A 49-51%, Customer B 24-30% of gross product revenue) poses risk if relationships are disrupted.

Next Steps

• FDA decision on EYLEA HD sBLA for RVO (November 2025).
• FDA decision on EYLEA HD sBLA for every 4-week dosing regimen (November 2025).
• EC decision on regulatory submission for Dupixent in CSU (Q4 2025).
• EC decision on regulatory submission for adjuvant CSCC (Libtayo) (Q4 2025).
• Initiate additional Phase 3 study for REGN5713-5715 (birch allergy) (Q4 2025).
• Submit BLA for garetosmab in FOP (Q4 2025).
• Submit BLA for DB-OTO (hearing deficit) (Q4 2025).
• FDA decision regarding new vial filler for EYLEA HD expected by late December 2025.
• Oral hearing concerning the '049 Patent (EYLEA) scheduled for December 2025.
• Submit application to include a new pre-filled syringe manufacturing filler for EYLEA HD by January 2026.
• Submit NDA for cemdisiran in myasthenia gravis (Q1 2026), pending discussions with FDA.
• Initiate additional Phase 3 study for REGN1908-1909 (cat allergy) (H1 2026).
• Report results from Phase 3 study versus pembrolizumab in first-line metastatic melanoma (Fianlimab) (H1 2026).
• Report data from Phase 2/3 studies in first-line advanced NSCLC (Fianlimab) (H1 2026).
• Initiate Phase 2 study (Fianlimab in combination with Libtayo) in first-line metastatic head and neck squamous cell carcinoma (H1 2026).
• Initiate Phase 3 studies for REGN9933 (thrombosis) (H1 2026).
• Initiate additional Phase 3 studies for REGN7508 (thrombosis) (H1 2026).
• EC decision on regulatory submission for Dupixent in bullous pemphigoid (H1 2026).
• Oral hearing before the Technical Board of Appeal of the EPO scheduled for April 2026 concerning Amgen's '797 Patent (Praluent).
• Oral argument on qui tam plaintiffs' appeal scheduled for November 18, 2025.

Key Dates

Recommendation

Regeneron demonstrates strong financial performance with increased net income and EPS, driven by robust growth in Dupixent and Libtayo, and continued uptake of EYLEA HD. The company's commitment to shareholder returns through dividends and significant share repurchases is also positive. However, the substantial decline in EYLEA sales due to biosimilar competition and patient affordability issues, coupled with critical regulatory delays for EYLEA HD and Ordspono stemming from manufacturing site inspections, introduce significant commercial and operational headwinds. The extensive and complex legal proceedings, including patent disputes, antitrust claims, and government investigations, create considerable uncertainty and potential for material adverse impacts. While the pipeline shows promise with several positive clinical readouts and BLA submissions planned, the mixed results for itepekimab and the temporary pause for Nexiguran ziclumeran highlight inherent drug development risks. Given the balance of strong growth in newer assets against the challenges of declining legacy product sales, regulatory hurdles, and a complex legal landscape, a 'hold' recommendation is appropriate for investors to monitor how these critical issues evolve.

Keywords

Biotechnology, Pharmaceuticals, Drug Development, EYLEA HD, EYLEA, Dupixent, Libtayo, Oncology, Ophthalmology, Immunology, Inflammation, Rare Diseases, Clinical Trials, FDA Approval, Biosimilars, Patent Litigation, Collaboration, Financial Results, Earnings, SEC Filing, REGN